Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

NCT06529250 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

148

Enrollment

OTHER

Sponsor class

Conditions

AML

Interventions

DRUG: HAD
DRUG: Daunorubicin+Cytarabine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China